Cytogenetic Analysis

Clinical cytogenetics involves the study of chromosomes, specifically examining their structure, function, inheritance, and abnormalities.
Chromosome abnormalities are a frequent cause of genetic disease, occurring in approximately 1-2% of live births, 5% of stillbirths, and 50% of early first-trimester fetal losses.
Standard cytogenetic analysis produces a karyotype (or karyogram), which is a digital representation of the entire genome's chromosomes paired and organized according to internationally accepted standard conventions based on length, banding pattern, and centromere position.

Cytogenetic evaluation is crucial for diagnosing numerous genetic, developmental, and reproductive conditions.

Clinical Category	Specific Indications
Pediatric / Developmental	Unexplained intellectual disability, global developmental delay, multiple congenital anomalies, dysmorphic features, ambiguous genitalia, and autism spectrum disorders.
Reproductive / Endocrine	Primary amenorrhea, infertility, recurrent miscarriages ($\geq$3), prior history of stillbirths or neonatal deaths.
Prenatal Testing	Advanced maternal age ($\geq$35 years), abnormal fetal ultrasound findings, unexplained fetal growth restriction.
Oncology / Hematology	Tumor surveillance (especially for leukemia using bone marrow aspirates) and evaluation for chromosome instability syndromes (e.g., Fanconi anemia, Bloom syndrome).

Chromosomes must be prepared from actively dividing cells during mitosis.
Tissue sources include peripheral blood lymphocytes, skin fibroblasts (from skin biopsy), bone marrow aspirates, solid tumor biopsies, amniotic fluid (amniocytes), chorionic villi, and fetal blood.
The laboratory process is highly labor-intensive and begins with culturing the cells, with or without specific stimulation.
Cells are artificially arrested in mitosis, typically during metaphase or prometaphase, using a chemical agent such as colecimid.
A hypotonic solution is applied to disrupt the nuclear cell membrane, allowing for the proper dispersion of chromosomes on a slide.
Slides are fixed and stained; the most widely used method is GTG banding (G bands by trypsin using Giemsa), which produces a unique pattern of dark (G-positive) and light (G-negative) bands for each chromosome pair.
A standard metaphase spread provides a resolution of 450 to 550 bands, allowing the detection of numerical abnormalities and structural anomalies down to approximately 5 Megabases (Mb) in size.
High-resolution analysis utilizes less-condensed prometaphase or prophase chromosomes to yield 550 to 850 bands, aiding in the detection of smaller abnormalities.

Molecular cytogenetics is utilized to detect subtle abnormalities that fall below the 5 Mb resolution limit of conventional karyotyping.

Technique	Principles and Clinical Utility
Fluorescence In Situ Hybridization (FISH)	Utilizes fluorochrome-labeled DNA probes (unique sequence, repetitive, or multiple-copy) that hybridize to complementary target sequences on metaphase chromosomes or interphase nuclei. It is used for rapid prenatal aneuploidy screening, sex assignment, and confirmation of microdeletion/microduplication syndromes.
Chromosomal Microarray (CMA) / aCGH	Differentially labels patient DNA (e.g., green dye) and reference DNA (e.g., red dye), hybridizing them to a microarray grid of oligonucleotides encompassing the entire genome. The fluorescence ratio detects copy number variations (CNVs). It offers up to 50-fold higher resolution than karyotyping and does not require dividing cells.
Single Nucleotide Polymorphism (SNP) Arrays	A type of CMA that evaluates polymorphic variations between nucleotides in parallel. It is highly useful for detecting uniparental disomy (genetic information derived from only one parent) and regions of consanguinity or loss of heterozygosity.
Multiplex Ligation-Dependent Probe Amplification (MLPA) & qPCR	Targeted molecular methods utilizing specific markers to rapidly detect submicroscopic chromosomal abnormalities within 1-2 days. Highly useful for rapid aneuploidy detection and identifying specific microdeletion syndromes.

CMA is currently recommended as the first-tier clinical diagnostic test for individuals with unexplained intellectual disability, autism spectrum disorders, and multiple congenital anomalies, replacing karyotyping for these indications.
While highly sensitive, CMA may detect variants of uncertain significance (VUS) or benign familial variants, often necessitating parental testing to interpret the clinical relevance of a detected CNV.
Conventional karyotyping remains essential for identifying balanced structural rearrangements (such as reciprocal translocations and inversions) that do not involve a net gain or loss of genetic material, which CMA cannot detect.